

INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Ronald B. Schwadron
	Filing Date: July 10, 2000	Group Art Unit: 4650 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

mtt	199	Aggarwal A, et al., Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura, South Med J. 2002 Oct;95(10):1209-12
mtt	200	Anderson D, et al., A Primatized MAb to Human CD4 Causes Receptor Modulation, without Marked Reduction in CD4 ⁺ T Cells in Chimpanzees: <i>In Vitro</i> and <i>in Vivo</i> Characterization of a MAb (IDEC-CE9.1) to Human CD4, Clinical Immunology and Immunopathology, Vol. 84, No. 1, July, pp 73-84, 1997, Article No. II974363
mtt	201	Anolik JH, et al., Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus, Arthritis Rheum. 2004 Nov;50(11):3580-90
mtt	202	Arzoo K, et al., Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab), Ann Rheum Dis 2002;61:922-924
mtt	203	Berrih S, et al., Interferon-gamma modulates HLA class II antigen expression on cultured human thymic epithelial cells, J Immunol. 1985 Aug;135(2):1165-71
mtt	204	Berentsen S, et al., Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients, Blood. 2004 Apr 15;103(8):2925-8
mtt	205	Bonilla FA, et al., Primary immunodeficiency diseases, J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S571-81
mtt	206	Buckley CD, Treatment of rheumatoid arthritis, BMJ Volume 315, 26 July 1997, pp 236-238
mtt	207	Buckley RH, Primary cellular immunodeficiencies, J Allergy Clin Immunol. 2002 May;109(5):747-57
mtt	208	Bujiah J, et al., Detection of class II antigens on human nasal cartilage, Am J Otolaryngol. 1990 Sep-Oct; 11(5):339-44
mtt	209	Choy EHS, et al., Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis, N Engl J Med, Vol. 344, No. 12, March 22, 2001, pp 907-915
mtt	210	Choy EHS, et al., Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial, Rheumatology 2002;41:1142-1148
mtt	211	Coll AP, et al., Rituximab therapy for the type B syndrome of severe insulin resistance, N Engl J Med. 2004 Jan 15;350(3):310-1
mtt	212	Cragg MS, et al., Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents, Blood, 1 April 2004, Volume 103, Number 7, pp 2738-2743
mtt	213	DeNardo GL, et al., Characterization of Human IgG Antimouse Antibody in Patients with B-Cell Malignancies, Clinical Cancer Research, Vol. 9, 4013s-4021s, September 1, 2003 (Suppl.)


EXAMINER: <u>Maher Haddad</u>	DATE CONSIDERED: <u>5/14/05</u>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 1 OF 6	



INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Ronald B. Schwadron
	Filing Date: July 10, 2000	Group Art Unit: 1636 1644

mtt	214	Dupuy A, et al., Treatment of refractory pemphigus vulgaris with rituximab (anti-Cd20 monoclonal antibody), Arch Dermatol. 2004 Jan;140(1):91-6
mtt	215	Edwards JCW, et al., Rheumatoid Arthritis: The Predictable Effect of Small Immune Complexes In Which Antibody Is Also Antigen, British Journal of Rheumatology 1998;37:126-130
mtt	216	Edwards JCW, et al., Do self-perpetuating B lymphocytes drive human autoimmune disease?, Immunology 1999;97:188-196
mtt	217	Edwards JCW, et al., Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis, The New England Journal of Medicine, June 17, 2004; 350:2572-71
mtt	218	Endo T, et al., Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient, Ann Hematol. 2004 Feb;83(2):114-6
mtt	219	Espana A, et al., Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations, J Am Acad Dermatol. 2004 Jun;50(6):974-6
mtt	220	Gajra A, et al., Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma, Am H. Hematol. 2004 Oct;77(2):196-7
mtt	221	Geha RS, Antibody deficiency syndromes and novel immunodeficiencies, Pediatr Infect Dis J. 1988 May;7(5 Suppl):S57-60
mtt	222	Goebeler M, et al., Rapid response for treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab, Br J Dermatol. 2003 Oct;149(4):899-901
mtt	223	Graus F, et al., Complex antigens in normal human dorsal root ganglia, J Neurol Sci. 1990 Sep;98(2-3):203-11
mtt	224	Harner KC, et al., Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjorgen's syndrome, Rheumatology (Oxford), 2004 Oct;43(10):1309-10
mtt	225	Heath M, et al., Evidence-based evaluation of immunology therapy for the cutaneous manifestations of lupus, Adv Dermatol. 2004;20:257-91
mtt	226	Hepburn TW, et al., Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis, Rheumatology 2003;42:544-61
mtt	227	Jonasson L, et al., Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis, J Clin Invest. 1985 Jul;76(1):125-31

EXAMINER <i>Maker Haddad</i>	DATE CONSIDERED <i>4/14/05</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 2 OF 6	



INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Ronald B. Schwadron
	Filing Date: July 10, 2000	Group Art Unit: 1636 1644

mH	228	Kawai T, et al., Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand, February 2000, Volume 6, Number 2, pp 1-4
mH	229	Kazkaz H, et al., Anti B cell therapy (rituximab) in the treatment of autoimmune diseases, Curr Opin Pharmacol. 2004 Aug;4(4):398-402
mH	230	Kinn SR, et al., Detection and quantation of HLA class II molecules on keratinocytes by quantitative immunofluorescence, J Immunol. Methods. 1990 Dec 5; 134(2):243-51
mH	231	Kon OM, et al., The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+T-cells in asthma. Eur Respir J 2001; 18:45-52
mH	232	Laguens G, et al., Demonstration and characterization of HLA-DR positive cells in the stroma of human endometrium, J Reprod Immunol. 1990 Sep;18(2):179-86
mH	233	Levy O, et al., Results of a Placebo-Controlled, Multicenter Trial Using a Primatized® Non-Depleting, Anti-CD4 Monoclonal Antibody in the Treatment of Rheumatoid Arthritis, American College of Rheumatology, Volume 39, No. 9 (Supplement) September 1996
mH	234	Lloyd RV, et al., Detection of HLA-DR antigens in paraffin-embedded thyroid epithelial cells with a monoclonal antibody, AM J Pathol. 1985 Jul;120(1):106-11
mH	235	Looney RJ, Treating human autoimmune disease by depleting B cells, Ann Rheum Dis 2002;61:863-866
mH	236	Looney RJ, et al., B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab, Arthritis Rheum. 2004 Aug;50(8):2580-9
mH	237	Looney RJ, et al., B cells as therapeutic targets for rheumatic diseases, Current Opinion in Rheumatology 2004, 16:180-185
mH	238	Maloney DC, et al., IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma, Blood, Vol 90, No 6, Sept. 15, 1997: pp 2188-2195
mH	239	Mavragani CP, et al., A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion, Rheumatology (Oxford). 2004 Nov;43(11):1450-1
mH	240	Moreland L, et al., Double-blind, Placebo-Controlled Multicenter Trial Using Chimeric Monoclonal Anti-CD4 Antibody, cM-T412, in Rheumatoid Arthritis Patients Receiving Concomitant Methotrexate, Arthritis & Rheumatism, Vol. 38, No. 11, November 1995, pp 1581-1588
mH	241	Ochs HD, et al., X-linked immunodeficiencies, Curr Allergy Asthma Rep. 2004 Sep;4(4):339-48
mH	242	Okamoto H, et al., Rituximab for rheumatoid arthritis, N Engl J Med. 2004 Oct 28;235(18):1909

EXAMINER

Maher Haddad

4/14/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-A820 (also form PTO-1449)


SHEET 3 OF 6



INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Ronald B. Schwadron
	Filing Date: July 10, 2000	Group Art Unit: 1630 1644

mt	243	Olsen NJ, et al. A Double-Blind, Placebo-Controlled Study of Anti-CD5 Immunoconjugate in Patients with Rheumatoid Arthritis, Arthritis & Rheumatism, Vol. 39, No. 7, July 1996, pp 1102-1108
mt	244	Oshima SE, Selective signal transduction through the CD3 or CD2 complex is required for class II MHC expression by human T cells, J. Immunol. 1990 Dec 15;145(12):4018-25
mt	245	Ottonello PM, et al., Monoclonal Lym-1 Antibody-Dependent Lysis of B-Lymphoblastoid Tumor Targets by Human Complement and Cytokine-Exposed Mononuclear and Neutrophilic Polymorphonuclear Leukocytes, Blood, Vol 87, No 12, June 15, 1996, pp 5171-5178
mt	246	Panayi GS, T-cell-dependent pathways in rheumatoid arthritis, Current Opinion in Rheumatology 1997; 9:236-240
mt	247	Papadakis KA, et al., Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune mediated thrombocytopenia associated with Crohn's disease, Gastroenterology. 2003 Feb;124(2):583
mt	248	Polyak M, et al., Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure, Blood, 1 May 2002, Volume 99, Number 9
mt	249	Pulczynski S, et al., Antibody-Induced Modulation and Intracellular Transport of CD10 and CD19 Antigens in Human Malignant B-Cell Lines, Leukemia and Lymphoma, 1993, Vol. 15, pp. 243-252
mt	250	Pulczynski S, Antibody-Induced Modulation and Intracellular Transport of CD10 and CD19 Antigens in Human B-Cell Lines: An immunofluorescence and Immunoelectron Microscopy Study, Blood, Vol. 81, No. 6 (March 15), 1993: pp 1549-1557
mt	251	Qian Gong, et al., Importance of Cellular Microenvironmental and Circulatory Dynamics in B Cell Immunotherapy, Journal of Immunology, 2005, 174: 817-826
mt	252	Quinn J, et al., Evan's syndrome complicating multicentric Castleman's disease - dramatic response to rituximab, Eur J Haematol. 2004 Nov;73(5):384-5
mt	253	Reid CD, et al., Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood, Blood. 1990 Sep 15;76(6):1139-49
mt	254	Rojas-Garcia R, et al., Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab, Neurology. 2003 Dec 23;61(12):1814-6
mt	255	Saigal K, et al., Hypocomplementemic urticarial vasculitis with angiodema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab, J Am Acad Dermatol. 2003 Nov;49(5 Suppl):S283-5


EXAMINER Mahn Haddad	DATE CONSIDERED 4/14/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 4 OF 6



INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Ronald B. Schwadron
	Filing Date: July 10, 2000	Group Art Unit: 1635 1644

mtt	256	Schadlow MB, et al., Using Rituximab (Anti-CD20 Antibody) in a Patient with Paraneoplastic Pemphigus, J Drugs Dermatol 2003; 2(5); 564-567
mtt	257	Schiff C, et al., Autosomal primary Immunodeficiencies affecting human bone marrow B-cell differentiation, Immunol Rev. 2000 Dec; 178:91-8
mtt	258	Schiff M, Emerging Treatments for Rheumatoid Arthritis, January 27, 1997, Volume 102, pp 1A-15S
mtt	259	Shan D, et al., Constitutive Endocytosis and Degradation of CD22 by Human B Cells, The Journal of Immunology, 1995, 154: 4466-4475
mtt	260	Shanafelt TD, et al., Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome, Mayo Clin Proc. 2003 Nov;78(11):1340-6
mtt	261	Shvidel L, et al., Intractable autoimmune hemolytic anemia B cell chronic lymphocytic leukemia resolved by Rituximab, Leuk Lymphoma. 2004 Jul;45(7):1493-4
mtt	262	Siddiqui K, et al., Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies, Neurology. 2003 Nov 11;61(9):1307-8
mtt	263	Tabibzadeh S, et al., Immunoreactivity of human endometrium: correlation with endometrial dating, Fertil Steril. 1990 Oct;55(4):624-31
mtt	264	Tedder FT, et al., The B Cell Surface Molecule B1 Is Functionally Linked With B Cell Activation And Differentiation, The Journal of Immunology, Vol. 135, No. 2, August 1985, pp 973-979
mtt	265	Todd I, et al. Interferon-gamma induces HLA-DR expression by thyroid epithelium, Clin Exp Immunol. 1985 Aug;61(2):265-73
mtt	266	Tsokos GC, B cells, be gone -B-cell depletion in the treatment of rheumatoid arthritis, N Engl J Med. 2004 Jun 17;350(25):2546-8
mtt	267	Uchida J, et al., The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor-dependent Mechanisms during Anti-Cd20 Antibody Immunotherapy, Journal of Experimental Medicine, Volume 199, Number 12, June 21, 2004, 1659-1669
mtt	268	Vaigot P, et al., Detection of distinct subpopulations of Langerhans cells by flow cytometry and sorting, Cytometry, 1985 Sep; 6(5):422-7
mtt	269	Virgolini L, et al., Anti-CD20 monoclonal antibody (rituximab) in the treatment in of autoimmune disease. Successful result in refractory Pemphigus vulgaris: report of a case, Haematologica. 2003 Jul;88(7)

EXAMINER	Mahm Haddad	DATE CONSIDERED	4/14/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO-A820 (also form PTO-1449)		SHEET 5 OF 6	



INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Ronald B. Schwadron
	Filing Date: July 10, 2000	Group Art Unit: 1636 1644

mt	270	Virgolini L, et al., Rituximab in autoimmune disease, Biomed Pharmacother. 2004 Jun;58(5):299-309
mt	271	Webster D, et al., Prompt Response to Rituximab of Severe Hemolytic Anemia With Both Cold and Warm Autoantibodies, American Journal of Hematology, 75:258-259 (2004)
mt	272	Wendling D, et al., A Randomized, Double Blind, Placebo Controlled Multicenter Trial of Murine Anti-CD4 Monoclonal Antibody Therapy in Rheumatoid Arthritis, The Journal of Rheumatology 1998; 25;8; 1458-1461
mt	273	Wicks I, et al., Autologous hemopoietic stem cell transplantation: A possible cure for rheumatoid arthritis?, Arthritis & Rheumatism, Vol. 40, No. 6, June 1997, pp 1005-1011
mt	274	Wylam ME, et al., Succesful treatment of refractory myasthenia gravis using rituximab: a pediatric case report, J Pediatr. 2003 Nov;143(5):674-7
mt	275	Xiao BG, Link H, Antigen-specific T cells in autoimmune diseases with a focus on multiple sclerosis and experimental allergic encephalomyelitis, CMLS, Cell. Mol. Life Sci. 56 (1999) 5-21
mt	276	Yocum DE, T Cells: Pathogenic Cells and Therapeutic Targets in Rheumatoid Arthritis, Seminars in Arthritis and Rheumatism, Vol 29, No 1, August, 1999: pp 27-35
mt	277	Yong VW, Morphologic heterogeneity of human adult astrocytes in culture: correlation with HLA-DR expression, J Neurosci Res. 1990 Dec; 27(4):678-88

EXAMINER: <i>Maker Hasblad</i>	DATE CONSIDERED <i>4/14/05</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 6 OF 6